Status
First check: what is the U.S. status?
The short version
As of September 2026, thymosin alpha-1 is not FDA approved and has no official U.S. drug label.
Pharmacies sometimes mix a medicine to order for one patient, which is called compounding. FDA keeps a short list of extra raw ingredients they may use for this, and thymosin alpha-1 is not on it.
Someone once asked FDA to let pharmacies use it, and later took that request back. Taking the request back did not make the ingredient approved or allowed.
Why the withdrawn request matters
An FDA page current as of April 22, 2026 lists thymosin alpha-1 among ingredients whose compounding requests were withdrawn.
FDA still prints a safety concern beside the ingredient. It says the body may treat the injected peptide as an invader, and that it lacks enough safety information to judge how serious the problems could be.
“Withdrawn” describes what happened to the request. It is not a green light, an approval, or a finding that the concerns disappeared.
What the public review found
An FDA advisory panel met in public in December 2024.
The ingredient comes in two slightly different chemical forms, and the panel voted on each one. Both times, seventeen members voted against adding it to the list of extra ingredients pharmacies may use.
Both times, four members voted in favor.
That advisory vote did not itself change the law; a formal FDA rule would be needed to change the list.
What an online offer could be
No approved U.S. product exists, so an American offer would involve pharmacy compounding, importation, or research-labeled material rather than an FDA-approved thymosin alpha-1 medicine.
Do not try to guess which of these you are being offered. Ask for the exact product and the pharmacy name, then check both.